Eisai acquires domestic approval of ‘Lenvima,’ thyroid cancer treatment

Eisai Korea(President Hong-byung Ko) announced Eisai, a global pharmaceutical company, has acquired approval for its newly developed antibiotics, ‘Lenvima Cap(generic name: lenvatinib),’ as treatment of progressive differentiated thyroid cancer which is resisted to radioactive iodine, recurrence or metastatic from the Ministry of Food and Drug Safety on the 7^th.

Thus, Lenvima was secondly appr...